Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries

Pharmacological Research

Volumn 63, Issue 3, 2011, Pages 199-206

  Siarkos, Ilias ^a   Urso, Vincenzo ^a   Sinagra, Tiziana ^a   Drago, Filippo ^a   Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Endothelium; Isolated femoral arteries; Telmisartan

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 CHLORO 5 NITROBENZANILIDE; ACETYLCHOLINE; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; INDOMETACIN; LOSARTAN; NITRIC OXIDE; PHENYLEPHRINE; PROSTANOID; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMORAL ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX;

ANIMALS; BENZIMIDAZOLES; BENZOATES; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; MALE; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASODILATION;

EID: 79751533327     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.10.010     Document Type: Article

References (58)

1. M. de Gasparo, K.J. Catt, T. Inagami, J.W. Wright, and T. Unger International union of pharmacology. Xxiii. The angiotensin II receptors Pharmacol Rev 52 2000 415 472
2. T. Unger The role of the renin-angiotensin system in the development of cardiovascular disease Am J Cardiol 89 2002 3A 9A
3. X.R. Huang, W.Y. Chen, L.D. Truong, and H.Y. Lan Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease J Am Soc Nephrol 14 2003 1738 1747 (Pubitemid 36750469)
4. C.M. Ferrario Use of angiotensin II receptor blockers in animal models of atherosclerosis Am J Hypertens 15 2002 9S 13S (Pubitemid 34098684)
5. L.M. Ruilope, J. Redon, and R. Schmieder Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs ACE inhibitors, or both? Expectations from the ONTARGET trial programme Vasc Health Risk Manag 3 2007 1 9 (Pubitemid 46863139)
6. L.H. Lindholm, H. Ibsen, B. Dahlof, R.B. Devereux, G. Beevers, and U. de Faire Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 1004 1010 (Pubitemid 34286537)
7. T. Berl, L.G. Hunsicker, J.B. Lewis, M.A. Pfeffer, J.G. Porush, and J.L. Rouleau Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 2003 542 549
8. S.E. Kjeldsen, and S. Julius Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Am Heart J 148 2004 747 754
9. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 2004 2054 2057 (Pubitemid 38620211)
10. S.C. Benson, H.A. Pershadsingh, C.I. Ho, A. Chittiboyina, P. Desai, and M. Pravenec Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPERgamma-modulating activity Hypertension 43 2004 993 1002 (Pubitemid 38579904)
11. G.A. Francis, E. Fayard, F. Picard, and J. Auwerx Nuclear receptors and the control of metabolism Annu Rev Physiol 65 2003 261 311 (Pubitemid 38249155)
12. R. Clasen, M. Schupp, A. Foryst-Ludwig, C. Sprang, M. Clemenz, and M. Krikov PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin Hypertension 46 2005 137 143 (Pubitemid 40946504)
13. Z.H. Israili Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 14 Suppl 1 2000 S73 86
14. Y. Higashi, K. Chayama, and M. Yoshizumi Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress Curr Med Chem Cardiovasc Hematol Agents 3 2005 133 148 (Pubitemid 40514788)
15. S. Salomone, E.M. Potts, S. Tyndall, P.C. Ip, J. Chun, and V. Brinkmann Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools Br J Pharmacol 153 2008 140 147
16. S. Salomone, G. Soydan, M.A. Moskowitz, and J.R. Sims Inhibition of cerebral vasoconstriction by dantrolene and nimodipine Neurocrit Care 10 2009 93 102
17. S. Salomone, G. Soydan, P.C. Ip, K.M. Hopson, and C. Waeber Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries Pharmacol Res 2010
18. M.J. Mulvany, and W. Halpern Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats Circ Res 41 1977 19 26 (Pubitemid 8132079)
19. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells Arterioscler Thromb Vasc Biol 23 2003 52 57 (Pubitemid 36091625)
20. N. Nagai, Y. Oike, K. Izumi-Nagai, T. Urano, Y. Kubota, and K. Noda Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization Arterioscler Thromb Vasc Biol 26 2006 2252 2259 (Pubitemid 44465719)
21. F. Scalera, J. Martens-Lobenhoffer, A. Bukowska, U. Lendeckel, M. Tager, and S.M. Bode-Boger Effect of telmisartan on nitric oxide - asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging Hypertension 51 2008 696 703 (Pubitemid 351301523)
22. T. Miyahara, L. Schrum, R. Rippe, S. Xiong, H.F. Yee Jr., and K. Motomura Peroxisome proliferator-activated receptors and hepatic stellate cell activation J Biol Chem 275 2000 35715 35722
23. S. Han, R.K. Wada, and N. Sidell Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma Cancer Res 61 2001 3998 4002 (Pubitemid 32720962)
24. J. Xu, O.A. Carretero, Y.H. Liu, E.G. Shesely, F. Yang, and A. Kapke Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice Hypertension 40 2002 244 250 (Pubitemid 35006705)
25. Y.H. Liu, X.P. Yang, E.G. Shesely, S.S. Sankey, and O.A. Carretero Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure J Am Coll Cardiol 43 2004 1473 1480 (Pubitemid 38496357)
26. R.A. Santos, A.J. Ferreira, and E.S.A.C. Simoes Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-mas axis Exp Physiol 93 2008 519 527 (Pubitemid 351595060)
27. N. Alenina, P. Xu, B. Rentzsch, E.L. Patkin, and M. Bader Genetically altered animal models for Mas and angiotensin-(1-7) Exp Physiol 93 2008 528 537 (Pubitemid 351595044)
28. D.T. Dudley, R.L. Panek, T.C. Major, G.H. Lu, R.F. Bruns, and B.A. Klinkefus Subclasses of angiotensin II binding sites and their functional significance Mol Pharmacol 38 1990 370 377 (Pubitemid 20291576)
29. J.F. Giani, M.M. Gironacci, M.C. Munoz, C. Pena, D. Turyn, and F.P. Dominici Angiotensin-(1-7) stimulates the phosphorylation of JAK2 IRS-1 and Akt in rat heart in vivo: Role of the AT1 and Mas receptors Am J Physiol Heart Circ Physiol 293 2007 H1154 H1163
30. W. Martin, R.F. Furchgott, G.M. Villani, and D. Jothianandan Depression of contractile responses in rat aorta by spontaneously released endothelium-derived relaxing factor J Pharmacol Exp Ther 237 1986 529 538 (Pubitemid 16092813)
31. H.M. Vargas, J.M. Cuevas, L.J. Ignarro, and G. Chaudhuri Comparison of the inhibitory potencies of N(G)-methyl-N(G)-nitro- and N(G)-amino-l-arginine on EDRF function in the rat: evidence for continuous basal EDRF release J Pharmacol Exp Ther 257 1991 1208 1215
32. S. Sola, M.Q. Mir, F.A. Cheema, N. Khan-Merchant, R.G. Menon, and S. Parthasarathy Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic acid in Endothelial Dysfunction (ISLAND) study Circulation 111 2005 343 348 (Pubitemid 40165342)
33. A.J. Flammer, F. Hermann, P. Wiesli, B. Schwegler, R. Chenevard, and D. Hurlimann Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension J Hypertens 25 2007 785 791 (Pubitemid 46398873)
34. S. Barra, A. Vitagliano, V. Cuomo, G. Vitagliano, and G. Gaeta Vascular and metabolic effects of angiotensin II receptor blockers Expert Opin Pharmacother 10 2009 173 189
35. H. Ikejima, T. Imanishi, H. Tsujioka, A. Kuroi, K. Kobayashi, and M. Shiomi Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change J Hypertens 26 2008 964 972 (Pubitemid 351520984)
36. N. Kobayashi, T. Ohno, K. Yoshida, H. Fukushima, Y. Mamada, and M. Nomura Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats Am J Hypertens 21 2008 576 581 (Pubitemid 351589680)
37. K. Goya, S. Sumitani, M. Otsuki, X. Xu, H. Yamamoto, and S. Kurebayashi The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells J Diabetes Complications 20 2006 336 342 (Pubitemid 44292533)
38. D.D. Sears, A. Hsiao, J.M. Ofrecio, J. Chapman, W. He, and J.M. Olefsky Selective modulation of promoter recruitment and transcriptional activity of PPARgamma Biochem Biophys Res Commun 364 2007 515 521 (Pubitemid 350026497)
39. M. Seimandi, G. Lemaire, A. Pillon, A. Perrin, I. Carlavan, and J.J. Voegel Differential responses of PPARalpha PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands Anal Biochem 344 2005 8 15 (Pubitemid 41569372)
40. S. Cianchetti, A. Del Fiorentino, R. Colognato, R. Di Stefano, F. Franzoni, and R. Pedrinelli Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells Atherosclerosis 198 2008 22 28 (Pubitemid 351406364)
41. M.D. Frame, R.J. Fox, D. Kim, A. Mohan, B.C. Berk, and C. Yan Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II Am J Physiol Heart Circ Physiol 282 2002 H2377 H2385
42. C. Zhang, T.W. Hein, W. Wang, and L. Kuo Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function Circ Res 92 2003 322 329 (Pubitemid 36258555)
43. S. Matsuhisa, H. Otani, T. Okazaki, K. Yamashita, Y. Akita, and D. Sato Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in dahl salt-sensitive rat heart Am J Physiol Heart Circ Physiol 294 2008 H2473 H2479
44. H. Fukushima, N. Kobayashi, H. Takeshima, W. Koguchi, and T. Ishimitsu Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure J Cardiovasc Pharmacol 55 2010 83 88
45. D.N. Atochin, A. Wang, V.W. Liu, J.D. Critchlow, A.P. Dantas, and R. Looft-Wilson The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo J Clin Invest 117 2007 1961 1967 (Pubitemid 47036330)
46. V. De Gennaro Colonna, A. Rigamonti, S. Fioretti, S. Bonomo, B. Manfredi, and P. Ferrario Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats Eur J Pharmacol 516 2005 253 259 (Pubitemid 40922746)
47. H.A. Peredo, M.A. Mayer, A. Carranza, and A.M. Puyo Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats Clin Exp Hypertens 30 2008 159 169 (Pubitemid 351302230)
48. V.J. Dzau Implications of local angiotensin production in cardiovascular physiology and pharmacology Am J Cardiol 59 1987 59A 65A (Pubitemid 17023340)
49. V.J. Dzau Circulating versus local renin-angiotensin system in cardiovascular homeostasis Circulation 77 1988 I4 13
50. T. Unger, and P. Gohlke Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors Am J Cardiol 65 1990 3I 10I (Pubitemid 20166444)
51. S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich ACE2 of the heart: from angiotensin I to angiotensin (1-7) Cardiovasc Res 73 2007 463 469 (Pubitemid 46091776)
52. K.B. Brosnihan, P. Li, E.A. Tallant, and C.M. Ferrario Angiotensin-(1-7): a novel vasodilator of the coronary circulation Biol Res 31 1998 227 234 (Pubitemid 28468273)
53. H.M. Siragy, and R.M. Carey The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats J Clin Invest 100 1997 264 269 (Pubitemid 27349072)
54. K.M. Gauthier, D.X. Zhang, E.M. Edwards, B. Holmes, and W.B. Campbell Angiotensin II dilates bovine adrenal cortical arterioles: role of endothelial nitric oxide Endocrinology 146 2005 3319 3324 (Pubitemid 41058103)
55. G. Servant, G. Boulay, R. Bosse, E. Escher, and G. Guillemette Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium Mol Pharmacol 43 1993 677 683 (Pubitemid 23146264)
56. E.A. Tallant, X. Lu, R.B. Weiss, M.C. Chappell, and C.M. Ferrario Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor Hypertension 29 1997 388 393 (Pubitemid 27074073)
57. M.W. Lo, M.R. Goldberg, J.B. McCrea, H. Lu, C.I. Furtek, and T.D. Bjornsson Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Clin Pharmacol Ther 58 1995 641 649 (Pubitemid 26018849)
58. J. Stangier, C.A. Su, and W. Roth Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients J Int Med Res 28 2000 149 167 (Pubitemid 30648951)